Valsartan Film-Coated Tablet 160 mg (Valsartan)

Adult dose

For essential hypertension, the recommended oral dose of valsartan is 80 mg once daily. If blood pressure control is inadequate, it can be increased up to 160 mg daily, with a maximum of 320 mg. Elderly patients (75 years and older) should start with 40 mg once daily. Patients with kidney disease, volume depletion, or liver disease each require dose adjustments, and those with severe liver disease and dialysis patients should not be treated.

This medication can cause serious harm to the fetus when taken during pregnancy, particularly in the second and third trimesters. If pregnancy is confirmed, discontinue use immediately. Women who are pregnant or may become pregnant, and breastfeeding women should not take this medication. Patients with severe liver dysfunction, cirrhosis, or biliary obstruction should avoid using this medication. Patients with hereditary angioedema or a history of angioedema should not use this medication. Patients with severely impaired kidney function, primary hyperaldosteronism, or certain kidney disorders associated with diabetes should not take this medication. Elderly patients, those with hyperkalemia, mild liver dysfunction, heart valve disease, or cardiovascular diseases should use this medication with caution. Patients with heart failure or after myocardial infarction should use this medication while closely observing changes in kidney function. This medication lowers blood pressure, and when taken for the first time, may cause a rapid drop in blood pressure leading to dizziness or fainting, so caution is needed. Patients undergoing hemodialysis or on strict sodium restriction, and those taking diuretics may be at risk for hypotension and should start at a low dose while closely monitoring their condition. This medication contains specific dye components, so patients with allergies to them should be cautious. Due to the risk of hyperkalemia, when combined with potassium-sparing diuretics or potassium supplements, blood potassium levels should be closely monitored. Taking this medication concurrently with non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the blood pressure-lowering effect and increase the risk of kidney dysfunction, so caution is advised. When taken with lithium preparations, lithium levels may increase, necessitating monitoring of blood lithium levels. This medication does not significantly affect the CYP450 enzyme system, hence the risk of metabolic interactions with other drugs is low, though interactions related to certain drug transporters in the liver may occur. Safety and efficacy in children and adolescents under 18 years of age have not been established. In case of overdose, severe hypotension, decreased consciousness, or shock may occur, and immediate medical treatment is required. Store this medication out of reach of children and avoid transferring it to other containers. Caution is necessary when driving or operating machinery, as symptoms such as dizziness may occur.

Serious side effects

Hives, severe swelling (edema), angioedema, chest tightness, difficulty breathing, cold sweat, pallor, severe rash accompanied by fever, blisters, skin peeling, pain in oral/ocular mucosa, shortness of breath or difficulty breathing, asthma attack, respiratory distress associated with cough and fever, jaundice (yellowing of skin or eyes), severe lethargy, sudden and severe headache, thunderclap headache, seizures, altered consciousness, visual disturbances

Mild side effects

• Headache
• dizziness
• viral infection
• upper respiratory tract infection
• cough
• diarrhea
• fatigue
• rhinitis
• sinusitis
• back pain

This medication should be stored in a tightly closed container to protect it from air and moisture. It is also important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance

Orange-yellow oblong film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle